Optical News

NAGOYA, Japan--(BUSINESS WIRE)--Menicon Co., Ltd. is pleased to announce that its new manufacturing facility in Kedah, Malaysia, has commenced commercial production. The plant strengthens Menicon’s long-standing commitment to technological excellence, uncompromising quality, and a stable global supply of contact lenses. The newly opened Malaysia plant is Menicon’s largest site to date and is dedicated exclusively to producing 1-DAY lenses. As global demand for 1-DAY lenses continues rising and...

NEW YORK--(BUSINESS WIRE)--Clinique, a globally leading dermatologist guided skincare to makeup brand,* today announces a visionary collaboration in the U.S. with ACUVUE, the world’s leading§ contact lens brand. It unites two global leaders around a powerful mission: to advance eye education in beauty and vision by highlighting to consumers that they can wear contacts and eye makeup confidently. This pioneering collaboration highlights Clinique’s expertise in creating high-performance eye makeu...

SALT LAKE CITY--(BUSINESS WIRE)--iVeena Delivery Systems, Inc. (“iVeena”), a clinical-stage ophthalmology company advancing innovative pharmacologic therapies for refractive eye diseases, today announced key executive promotions designed to strengthen operational leadership and advance its scientific vision. Effective immediately, Michael Burr, M.B.A., M.S., has been promoted to Chief Operating Officer (COO), and Sarah Molokhia, R.Ph., Ph.D., has been promoted to Chief Scientific Officer (CSO)....

MISSOULA, Mont.--(BUSINESS WIRE)--OSRX remains licensed and operational in California, continuing uninterrupted access to compounded ophthalmic medications....

TORONTO--(BUSINESS WIRE)--Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced the Canadian launch of PRECISION7® sphere and toric, the only one-week replacement contact lens with the revolutionary ACTIV-FLO® System2,5 that provides 16 hours of outstanding comfort and precise vision, even on day 7.1 The lenses will be commercially available in Canada in February. While nearly nine out of ten Eye Care Professionals (ECPs) believe daily...

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (“STAAR” or the “Company”) (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that its Board of Directors (the “Board”) has appointed Warren Foust, President and Chief Operating Officer, and Deborah Andrews, Chief Financial Officer, as interim co-Chief Executive Officers, effective February 1, 2026. Mr. Foust and Ms. Andrews will work t...

LONDON--(BUSINESS WIRE)--Automata, the lab automation company building fully integrated, AI-ready platforms for life sciences, today announced the close of a $45 million Series C funding round led by Dimension with participation from Danaher Ventures, Tru Arrow Partners, Octopus Ventures, Entrepreneurs First, and others. The round also includes a strategic investment partnership with Danaher Corporation, with Murali Venkatesan Ph.D., Global Head of Danaher Ventures and Vice President of Science...

LONDON & SEATTLE--(BUSINESS WIRE)--Tenpoint Therapeutics, Ltd., a global, commercial biotechnology company focused on developing groundbreaking treatments to rejuvenate vision in the aging eye, today announced it has secured $235 million through the successful close of its Series B preferred stock financing and a credit facility. The Company raised $85 million in Series B financing led by Janus Henderson, EQT Nexus, Hillhouse and British Business Bank. Existing investors also participating incl...

LONDON & SEATTLE--(BUSINESS WIRE)--Tenpoint Therapeutics, Ltd., a global, commercial biotechnology company focused on developing groundbreaking treatments to improve vision in the aging eye, today announced that the U.S. Food and Drug Administration (FDA) approved YUVEZZI™ (carbachol and brimonidine tartrate ophthalmic solution) 2.75%/0.1%, previously known as BRIMOCHOL™ PF, the first and only dual-agent eye drop for the treatment of presbyopia in adults. Presbyopia, the gradual loss of near vi...

PARIS--(BUSINESS WIRE)--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, announced that its Extraordinary General Meeting held today at 3:00 p.m. approved all resolutions submitted to shareholders, with the exception of the 8th resolution relating to a reserved capital increase, which was...